Unresectable Hepatocellular Carcinoma

Oncology
2
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Chengdu New Radiomedicine
2 programs
1
1
NRT6003 InjectionPhase 31 trial
NRT6003 InjectionPhase 11 trial
Active Trials
NCT06310590CompletedEst. Jun 2025
NCT06900543RecruitingEst. Dec 2027
Bayer
BayerLEVERKUSEN, Germany
1 program
AtezolizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06117891Recruiting300Est. Feb 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyN/A1 trial
Active Trials
NCT05667064Completed1,200Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Chengdu New RadiomedicineNRT6003 Injection
Chengdu New RadiomedicineNRT6003 Injection
BayerAtezolizumab
AstraZenecaImfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Clinical Trials (4)

Total enrollment: 1,500 patients across 4 trials

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Start: Apr 2025Est. completion: Dec 2027
Phase 3Recruiting

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

Start: Aug 2023Est. completion: Jun 2025
Phase 1Completed
NCT06117891BayerAtezolizumab

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Start: Nov 2023Est. completion: Feb 2027300 patients
N/ARecruiting
NCT05667064AstraZenecaImfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Start: May 2023Est. completion: Jul 20251,200 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,500 patients
3 companies competing in this space